{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:43:11Z","timestamp":1789706591048,"version":"4.0.1"},"reference-count":39,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Background:<\/i><\/b> Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis that significantly impairs physical function and quality of life (QoL). Prompt therapeutic intervention is crucial for limiting PsA progression and preventing disability. <b><i>Objectives:<\/i><\/b> The aim of this study was to compare the efficacy of brodalumab versus ustekin\u00adumab and the impact on QoL in patients with moderate-to-severe plaque psoriasis, by concomitant PsA status. <b><i>Methods:<\/i><\/b> This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials evaluated complete skin clearance (100% improvement of Psoriasis Area and Severity Index [PASI 100]), improvement in symptom severity (Psoriasis Symptom Inventory [PSI] response), and QoL (Dermatology Life Quality Index [DLQI] score of 0\/1) by concomitant PsA status. A competing risk model assessed cumulative incidence over 52 weeks with outcomes of PASI 100 or inadequate response. <b><i>Results:<\/i><\/b> This analysis included 929 patients with moderate-to-severe psoriasis. Concomitant PsA was present in 79\/339 (23%) and 110\/590 (19%) patients receiving brodalumab 210 mg and ustekinumab, respectively. At Week 52, odds ratios (ORs) (95% confidence intervals [CIs]) for complete clearance with brodalumab versus ustekin\u00adumab were 3.15 (1.52\u20136.55, <i>p<\/i> = 0.0015) in patients with concomitant PsA and 3.05 (2.19\u20134.26, <i>p<\/i> &#x3c; 0.0001) in patients without concomitant PsA. Corresponding Week 52 ORs (95% CIs) for DLQI 0\/1 with brodalumab versus ustekinumab were 2.05 (1.07\u20133.90, <i>p<\/i> = 0.0277) and 1.83 (1.32\u20132.53, <i>p<\/i> = 0.0002); Week 52 ORs (95% CIs) for PSI \u22648 with brodalumab versus ustekinumab were 3.42 (1.43\u20138.18, <i>p<\/i> = 0.0036) and 1.40 (1.01\u20131.95, <i>p<\/i> = 0.0434). The 52-week cumulative incidence of patients achieving PASI 100 was significantly higher for brodalumab versus ustekinumab in patients with concomitant PsA (<i>p<\/i> = 0.0001) and in those without concomitant PsA (<i>p<\/i> &#x3c; 0.0001). <b><i>Conclusions:<\/i><\/b> Treatment with brodalumab rapidly results in high levels of complete and sustained skin clearance and greater cumulative treatment benefit in patients with moderate-to-severe psoriasis versus ustekinumab, regardless of concomitant PsA status. <\/jats:p>","DOI":"10.1159\/000520290","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T09:56:14Z","timestamp":1644314174000},"page":"620-629","source":"Crossref","is-referenced-by-count":8,"title":["Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis"],"prefix":"10.1159","volume":"238","author":[{"given":"Georgios","family":"Kokolakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-0536","authenticated-orcid":false,"given":"Kasper","family":"Vadstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes B.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16332"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3908-y"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0256-0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8630-7"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02277-x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19144.1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0215-7"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200126"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301737"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317738910"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0254-4"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.742950"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1214667"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16816"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1093589"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.880396"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00428-1"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1159\/000113150"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.001"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.943687"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903085328"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.038"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2018.77725"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.10.009"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03361.x"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/520290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:27:58Z","timestamp":1745422078000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000520290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2022,7,6]]}},"URL":"https:\/\/doi.org\/10.1159\/000520290","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.17081129","asserted-by":"subject"}]},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]}}}